Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Interventional Phase 3, Open-label, Two-cohort Study to Investigate the Efficacy and Safety of Fosmanogepix in Adult Patients With Invasive Mold Infections Caused by Aspergillus Spp., Fusarium Spp., Lomentospora Prolificans, Mucorales Fungi, or Other Multidrug Resistant Molds

NCT06925321 is registered in ClinicalTrials.gov with Basilea Pharmaceutica as lead sponsor.

NCT NCT06925321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06925321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Interventional Phase 3, Open-label, Two-cohort Study to Investigate the Efficacy and Safety of Fosmanogepix in Adult Patients With Invasive Mold Infections Caused by Aspergillus Spp., Fusarium Spp., Lomentospora Prolificans, Mucorales Fungi, or Other Multidrug Resistant Molds
Lead sponsor
Basilea Pharmaceutica
Phase
Phase 3
Overall status
Recruiting
Start date
August 26, 2025
Completion date
February 29, 2028
Enrollment
234 (estimated)
Sites
84

Conditions

As the registry lists them; a condition with its own page is linked.

invasive mold infections